Lansing-based Emergent BioSolutions Inc. signed a government contract to produce 14.5 million Anthrax vaccines, an agreement worth more than $364 million.
According to excerpts from the article:
Emergent likely would begin delivering the vaccine in the third quarter of 2009 after it has filled a previous $448 million U.S. Department of Health & Human Services order for 18.75 million doses of the BioThrax vaccine.
It likely would take until the third quarter of 2011 to fulfill the new order.
The vaccine from both orders is being included into a stockpile of vaccines and medications that could be needed in the event of a biological terrorist attack.
The value of the new contract could range from $364 million to $404 million, with the higher amount tied to delivery of a vaccine that has a shelf life of four years.
Read the entire article here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.